Akonni receives $150,000 Phase I NSF grant to assess feasibility of developing lab-on-a-film microarray device Akonni Biosystems, a molecular diagnostics company that develops, manufactures, and plans to market sophisticated molecular testing products for diagnosing infectious diseases and human genetic disorders, announced today the receipt of a $150,000 Phase I Grant from the National Technology Foundation . This preliminary round of financing from NSF will enable Akonni to measure the feasibility of developing a lab-on-a-film microarray gadget that can be stated in a reel-to-reel format. This means that that, with tightening ballooning and budgets projections for diagnostic testing, another technical revolutions in molecular diagnostics must deliver considerable reductions in per check cost.Writing in an accompanying content, John Metcalfe, of the University of California, SAN FRANCISCO BAY AREA, and colleagues said: ‘If replicated, [this study] could have important implications to get global TB treatment in moving away from witnessed dosing, which is not feasible universally, towards a far more personalized adherence model of patient-provider communication in which intervention is delivered where, when, and in whom it is needed to prevent adverse treatment outcome efficiently.’.
1 percent of adults encounter headaches associated with sex, shows report About 1 % of adults report they have experienced headaches associated with sexual activity, and that such headaches could be severe. However the actual incidence is almost higher certainly, according to a Loyola University INFIRMARY headache and neurologist specialist.